Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:ACRV NASDAQ:BCYC NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.68-3.2%$5.04$4.00▼$7.54$322.79M1.351.19 million shs636,674 shsACRVAcrivon Therapeutics$1.91-0.3%$1.67$1.05▼$3.56$81.53M2.011.43 million shs161,643 shsBCYCBicycle Therapeutics$4.67-0.7%$4.95$4.24▼$9.36$325.13M1.56418,090 shs173,058 shsPALIPalisade Bio$1.95+0.3%$1.98$0.53▼$2.86$325.64M1.524.29 million shs1.44 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.68%+7.92%+19.35%+14.45%+11.20%ACRVAcrivon Therapeutics-3.54%-8.61%+22.44%+22.44%+64.66%BCYCBicycle Therapeutics-2.29%-2.08%-4.86%-16.52%-43.65%PALIPalisade Bio+7.78%-2.51%+6.59%+12.14%+167.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.68-3.2%$5.04$4.00▼$7.54$322.79M1.351.19 million shs636,674 shsACRVAcrivon Therapeutics$1.91-0.3%$1.67$1.05▼$3.56$81.53M2.011.43 million shs161,643 shsBCYCBicycle Therapeutics$4.67-0.7%$4.95$4.24▼$9.36$325.13M1.56418,090 shs173,058 shsPALIPalisade Bio$1.95+0.3%$1.98$0.53▼$2.86$325.64M1.524.29 million shs1.44 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.68%+7.92%+19.35%+14.45%+11.20%ACRVAcrivon Therapeutics-3.54%-8.61%+22.44%+22.44%+64.66%BCYCBicycle Therapeutics-2.29%-2.08%-4.86%-16.52%-43.65%PALIPalisade Bio+7.78%-2.51%+6.59%+12.14%+167.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.60Moderate Buy$19.00236.58% UpsideACRVAcrivon Therapeutics 2.50Moderate Buy$11.67512.42% UpsideBCYCBicycle Therapeutics 2.44Hold$14.00201.40% UpsidePALIPalisade Bio 2.88Moderate Buy$10.20427.13% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, PALI, BCYC, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/27/2026ACRVAcrivon Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/10/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026BCYCBicycle Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$13.00 ➝ $12.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/19/2026ABEOAbeona Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/18/2026BCYCBicycle Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $36.003/18/2026BCYCBicycle Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$11.00 ➝ $7.003/18/2026BCYCBicycle Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $8.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M55.17N/AN/A$2.94 per share1.92ACRVAcrivon TherapeuticsN/AN/AN/AN/A$3.57 per shareN/ABCYCBicycle Therapeutics$72.86M4.44N/AN/A$8.79 per share0.53PALIPalisade BioN/AN/AN/AN/A$0.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$1.035.4831.36N/AN/A-60.65%-40.78%5/13/2026 (Estimated)ACRVAcrivon Therapeutics-$77.90M-$2.02N/AN/AN/AN/A-57.23%-51.09%5/13/2026 (Estimated)BCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%N/APALIPalisade Bio-$16.78M-$2.12N/AN/AN/AN/A-47.76%-42.98%N/ALatest ACRV, PALI, BCYC, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.33N/AN/AN/A$4.57 millionN/A5/13/2026Q1 2026ACRVAcrivon Therapeutics-$0.49N/AN/AN/A$0.28 millionN/A4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/19/2026Q4 2025ACRVAcrivon Therapeutics-$0.49-$0.49N/A-$0.49$0.17 millionN/A3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 million3/17/2026Q4 2025ABEOAbeona Therapeutics-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.056.936.74ACRVAcrivon TherapeuticsN/A7.697.69BCYCBicycle TherapeuticsN/A12.6612.66PALIPalisade BioN/A28.9528.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ACRVAcrivon Therapeutics71.62%BCYCBicycle Therapeutics86.15%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%ACRVAcrivon Therapeutics8.50%BCYCBicycle Therapeutics8.50%PALIPalisade Bio0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.88 million53.81 millionOptionableACRVAcrivon Therapeutics5842.80 million39.16 millionNot OptionableBCYCBicycle Therapeutics24069.71 million63.78 millionOptionablePALIPalisade Bio10167.42 million167.31 millionNot OptionableACRV, PALI, BCYC, and ABEO HeadlinesRecent News About These CompaniesPalisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6, 2026 | americanbankingnews.comPalisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 6, 2026 | marketbeat.comPalisade Bio reports phase 1a/b data showing colon‑targeted exposureMay 5, 2026 | pharmatimes.comPPalisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisMay 5, 2026 | globenewswire.comPalisade Bio (PALI) Expected to Announce Earnings on MondayMay 4, 2026 | marketbeat.comPalisade Bio (PALI) price target decreased by 12.09% to 10.20April 29, 2026 | msn.comAnalysts Offer Predictions for Palisade Bio Q1 EarningsApril 21, 2026 | marketbeat.comBrokers Issue Forecasts for Palisade Bio Q3 EarningsApril 20, 2026 | marketbeat.comWolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical ProfileApril 17, 2026 | insidermonkey.comPalisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative ColitisApril 16, 2026 | quiverquant.comQPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026April 16, 2026 | globenewswire.comWolfe Research initiates coverage of Palisade Bio (PALI) with outperform recommendationApril 10, 2026 | msn.comPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceApril 8, 2026 | globenewswire.comPalisade Bio partners with Iterative Health to advance PALI-2108April 2, 2026 | tipranks.comPalisade Bio drops after early-stage trial data for lead assetMarch 31, 2026 | msn.comPalisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s DiseaseMarch 30, 2026 | markets.businessinsider.comPalisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's DiseaseMarch 30, 2026 | globenewswire.comHC Wainwright & Co. initiates coverage of Palisade Bio (PALI) with buy recommendationMarch 27, 2026 | msn.comPalisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy RatingMarch 23, 2026 | seekingalpha.comPalisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patientsMarch 19, 2026 | msn.comPalisade Bio Announces Participation in Two Upcoming Investor ConferencesMarch 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, PALI, BCYC, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.68 -0.19 (-3.16%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Acrivon Therapeutics NASDAQ:ACRV$1.90 -0.01 (-0.26%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Bicycle Therapeutics NASDAQ:BCYC$4.66 -0.04 (-0.74%) As of 02:38 PM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Palisade Bio NASDAQ:PALI$1.94 +0.01 (+0.26%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas On Holdings Sets Up for Marathon Rally: New Highs Are Coming Shake Shack Stock Gets Shaken After Earnings Miss Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? MP Materials Is Quietly Building a Rare Earth Powerhouse The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000 Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
